CellCarta has developed and validated over 200 assays which have been tested and used in numerous exploratory projects and clinical trials, including global Phase III projects.
Our team of board-certified pathologists, deeply experienced imaging scientists, and laboratory technologists have developed a proven process for IHC/IF assay development which is embedded into our quality systems.
We provide complete IHC and IF assay development services, from the selection of high-quality antibodies, to proper selection of platforms, control tissues, and experimental conditions to obtain the best signals.
At CellCarta, we adopt a full accountability philosophy for our assay development projects. While we select high quality antibody vendors, CellCarta has established SOPs guiding the quality of the reagents, including detecting variations from reagent lots.
Our approach to assay development is customizable and optimized to your needs and validation requirements. A complete validation report including assay precision, specificity, and performance can be provided and the final protocol is locked and described in an SOP.
CellCarta automates its IHC and IF assays to minimize variability and increase productivity and capacity. The following automated staining platforms are currently available.
With multiplexed IHC, you interrogate multiple targets on a single slide, obtaining quantitative and actionable results, and leveraging often limited tissue specimens. Multiplex IF offers a solution for the study of multiple targets on a single slide, where the targets are expressed on the same cellular compartment.
Advantages of our standardized workflow: